Immune-based combination therapy for metastatic kidney cancer

Camillo Porta^{1

2}, Mimma Rizzo³

Affiliations

¹ Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. camillo.porta@unipv.it.
² Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy. camillo.porta@unipv.it.
³ Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.

Comment

Camillo Porta et al. Nat Rev Nephrol. 2019 Jun.

. 2019 Jun;15(6):324-325.

doi: 10.1038/s41581-019-0149-0.

Camillo Porta^{1

2}, Mimma Rizzo³

¹ Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. camillo.porta@unipv.it.
² Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy. camillo.porta@unipv.it.
³ Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy.

No abstract available

Comment on

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Motzer RJ, et al. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779531 Free PMC article. Clinical Trial.